Nueraili Maihemuti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Nueraili Maihemuti has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Yueli Shi
Zhejiang Chinese Medical University
2 shared publications- Zhiyong Xu
Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Zhejiang University School of Medicine, Yiwu, China
2 shared publications Jiahe Chu
Department of Respiratory and Critical Care Medicine Center for Oncology Medicine the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University Yiwu China
1 shared publication- Kai Wang
University of Pennsylvania
1 shared publication Kaiyue Zhang
Department of Respiratory and Critical Care Medicine Center for Oncology Medicine the Fourth Affiliated Hospital of School of Medicine, and International School of Medicine, International Institutes of Medicine, Zhejiang University Yiwu China
1 shared publicationPan Liu
Chinese Academy of Sciences
1 shared publication
Latest Publications
- Open Access
- 31 October 2025
- Published by Springer Nature in Research Square
FCRLB-mediated dual control of tumor metabolism and macrophage polarization promotes lung cancer malignancy
Background Anti–PD-1 therapy has improved outcomes in non-small cell lung cancer (NSCLC), yet primary and acquired resistance remain common. Pinpointing regulators of tumor–immune crosstalk is therefore critical to enhance therapeutic efficacy. Methods We integrated multi-omics sequencing with ensemble machine-learning to nominate prognostic genes in NSCLC, followed by pathway and intercellular-signaling analyses (pseudotime analysis, GSVA, and functional enrichment). We generated shRNA-mediated FCRLB-knockdown NSCLC cell lines and performed molecular and immunological assays. A murine lung-cancer xenograft model was used to validate the role of the candidate gene in tumor progression and its impact on the tumor microenvironment (TME). Results We identified FCRLB as a key gene influencing lung cancer prognosis via transcriptomic gene screening, and elucidated its unique roles in tumor cells and macrophages. FCRLB-highly expressing tumor cells exhibited high activation of the PI3K signaling and reactive oxygen species (ROS) pathways, regulated metabolic pathways such as pyridine metabolism and terpenoid quinone biosynthesis, and induced C-C motif chemokine ligand 2 (CCL2) production. Additionally, high FCRLB expression in monocyte-derived macrophages (mo-Macs) promoted M2-like polarization, thereby further exacerbating lung cancer malignancy. Conclusions Our data identify and functionally validate FCRLB as a pro-tumor regulator in NSCLC.FCRLB regulates the secretion of multiple cytokines (including CCL2) by tumor cells via the ROS pathway and PI3K signaling pathway, thereby promoting M2 polarization of macrophages. Additionally, FCRLB exerts a positive regulatory effect on the malignant progression of NSCLC. This finding provides a potential novel target for overcoming immunotherapys resistance in NSCLC.
- 31 October 2025
- Published by Springer Nature in Research Square
Open AccessFCRLB-mediated dual control of tumor metabolism and macrophage polarization promotes lung cancer malignancy
Background Anti–PD-1 therapy has improved outcomes in non-small cell lung cancer (NSCLC), yet primary and acquired resistance remain common. Pinpointing regulators of tumor–immune crosstalk is therefore critical to enhance therapeutic efficacy. Methods We integrated multi-omics sequencing with ensemble machine-learning to nominate prognostic genes in NSCLC, followed by pathway and intercellular-signaling analyses (pseudotime analysis, GSVA, and functional enrichment). We generated shRNA-mediated FCRLB-knockdown NSCLC cell lines and performed molecular and immunological assays. A murine lung-cancer xenograft model was used to validate the role of the candidate gene in tumor progression and its impact on the tumor microenvironment (TME). Results We identified FCRLB as a key gene influencing lung cancer prognosis via transcriptomic gene screening, and elucidated its unique roles in tumor cells and macrophages. FCRLB-highly expressing tumor cells exhibited high activation of the PI3K signaling and reactive oxygen species (ROS) pathways, regulated metabolic pathways such as pyridine metabolism and terpenoid quinone biosynthesis, and induced C-C motif chemokine ligand 2 (CCL2) production. Additionally, high FCRLB expression in monocyte-derived macrophages (mo-Macs) promoted M2-like polarization, thereby further exacerbating lung cancer malignancy. Conclusions Our data identify and functionally validate FCRLB as a pro-tumor regulator in NSCLC.FCRLB regulates the secretion of multiple cytokines (including CCL2) by tumor cells via the ROS pathway and PI3K signaling pathway, thereby promoting M2 polarization of macrophages. Additionally, FCRLB exerts a positive regulatory effect on the malignant progression of NSCLC. This finding provides a potential novel target for overcoming immunotherapys resistance in NSCLC.
- Open Access
Toll‐Like Receptors in the Immunotherapy Era: Dual‐Edged Swords of Tumor Immunity and Clinical Translation
Toll‐like receptors (TLRs), which are critical components of innate immunity, play a significant role in immune responses and deepen our understanding of TLRs. TLRs are a group of transmembrane proteins with similar structures distributed on the cell membrane and endosomes. They trigger downstream acute or chronic inflammatory responses by recognizing different types of pathogen‐associated molecular patterns and damage‐associated molecular patterns. TLRs play pivotal regulatory roles in various tumor types. Over the past few decades, research on TLRs has become increasingly popular, and these molecules can not only directly recognize tumor components as potential targets to activate antitumor immune responses but also act as accomplices to tumor progression and even as driver genes in certain tumor types. Despite their importance, the mechanisms underlying their dual functions remain poorly understood, creating a gap in current research. Here, we summarize the latest advancements in TLR signaling pathways and their application in tumor therapy in recent years, and highlight the development prospects and potential of TLRs in tumor therapy. Moreover, this review underscores the critical regulatory roles of TLRs across various tumor types and explores their prospects in oncology, offering valuable insights for developing targeted therapies and improving cancer outcomes.
Open AccessToll‐Like Receptors in the Immunotherapy Era: Dual‐Edged Swords of Tumor Immunity and Clinical Translation
Toll‐like receptors (TLRs), which are critical components of innate immunity, play a significant role in immune responses and deepen our understanding of TLRs. TLRs are a group of transmembrane proteins with similar structures distributed on the cell membrane and endosomes. They trigger downstream acute or chronic inflammatory responses by recognizing different types of pathogen‐associated molecular patterns and damage‐associated molecular patterns. TLRs play pivotal regulatory roles in various tumor types. Over the past few decades, research on TLRs has become increasingly popular, and these molecules can not only directly recognize tumor components as potential targets to activate antitumor immune responses but also act as accomplices to tumor progression and even as driver genes in certain tumor types. Despite their importance, the mechanisms underlying their dual functions remain poorly understood, creating a gap in current research. Here, we summarize the latest advancements in TLR signaling pathways and their application in tumor therapy in recent years, and highlight the development prospects and potential of TLRs in tumor therapy. Moreover, this review underscores the critical regulatory roles of TLRs across various tumor types and explores their prospects in oncology, offering valuable insights for developing targeted therapies and improving cancer outcomes.